Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 20 studies | 24% ± 6% | |
connective tissue cell | 4 studies | 26% ± 6% | |
adventitial cell | 4 studies | 37% ± 8% |
Insufficient scRNA-seq data for expression of HTRA3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 99% | 5637.63 | 455 / 459 | 92% | 119.63 | 1026 / 1118 |
lung | 98% | 4303.99 | 569 / 578 | 89% | 70.04 | 1032 / 1155 |
intestine | 92% | 2894.04 | 884 / 966 | 81% | 58.79 | 427 / 527 |
uterus | 99% | 4497.98 | 169 / 170 | 66% | 55.78 | 305 / 459 |
esophagus | 83% | 4164.99 | 1200 / 1445 | 82% | 61.09 | 150 / 183 |
bladder | 90% | 6865.57 | 19 / 21 | 68% | 59.44 | 343 / 504 |
prostate | 92% | 3090.90 | 225 / 245 | 67% | 22.80 | 334 / 502 |
stomach | 68% | 1955.30 | 245 / 359 | 84% | 61.30 | 240 / 286 |
ovary | 100% | 9941.07 | 180 / 180 | 46% | 18.00 | 196 / 430 |
thymus | 97% | 3230.55 | 635 / 653 | 37% | 14.41 | 221 / 605 |
skin | 74% | 2093.92 | 1344 / 1809 | 41% | 22.52 | 194 / 472 |
pancreas | 10% | 156.27 | 32 / 328 | 93% | 210.84 | 165 / 178 |
ureter | 0% | 0 | 0 / 0 | 100% | 17.68 | 1 / 1 |
heart | 100% | 11230.33 | 859 / 861 | 0% | 0 | 0 / 0 |
adipose | 100% | 7007.96 | 1201 / 1204 | 0% | 0 | 0 / 0 |
muscle | 90% | 1592.79 | 719 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 62% | 2170.56 | 828 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 56% | 36.35 | 25 / 45 |
adrenal gland | 31% | 372.50 | 79 / 258 | 11% | 5.46 | 26 / 230 |
lymph node | 0% | 0 | 0 / 0 | 41% | 20.44 | 12 / 29 |
kidney | 20% | 271.06 | 18 / 89 | 12% | 3.43 | 105 / 901 |
liver | 1% | 31.01 | 3 / 226 | 20% | 8.83 | 83 / 406 |
eye | 0% | 0 | 0 / 0 | 16% | 3.55 | 13 / 80 |
peripheral blood | 8% | 84.15 | 74 / 929 | 0% | 0 | 0 / 0 |
brain | 0% | 0 | 0 / 2642 | 8% | 2.19 | 56 / 705 |
spleen | 5% | 56.41 | 12 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030514 | Biological process | negative regulation of BMP signaling pathway |
GO_0030512 | Biological process | negative regulation of transforming growth factor beta receptor signaling pathway |
GO_0006508 | Biological process | proteolysis |
GO_0005576 | Cellular component | extracellular region |
GO_0008236 | Molecular function | serine-type peptidase activity |
GO_0004175 | Molecular function | endopeptidase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
GO_0004252 | Molecular function | serine-type endopeptidase activity |
Gene name | HTRA3 |
Protein name | Serine protease HTRA3 (EC 3.4.21.-) (High-temperature requirement factor A3) (Pregnancy-related serine protease) |
Synonyms | PRSP |
Description | FUNCTION: Serine protease that cleaves beta-casein/CSN2 as well as several extracellular matrix (ECM) proteoglycans such as decorin/DCN, biglycan/BGN and fibronectin/FN1. Inhibits signaling mediated by TGF-beta family proteins possibly indirectly by degradation of these ECM proteoglycans (By similarity). May act as a tumor suppressor. Negatively regulates, in vitro, trophoblast invasion during placental development and may be involved in the development of the placenta in vivo. May also have a role in ovarian development, granulosa cell differentiation and luteinization . . |
Accessions | P83110 ENST00000382512.3 [P83110-2] ENST00000307358.7 [P83110-1] |